

Rapid Mixed-Mode SPE Method Development of Tyrosine Kinase Inhibitor Oncology Pharmaceuticals Oasis™ Method Development Plate

Mary Trudeau, Margot Lee

Waters Corporation

Abstract

The following work demonstrates the fast mixed-mode SPE screening approach for bioanalytical sample preparation, achieving high recovery and selectivity of several block-buster small molecule oncology therapeutic drugs from plasma using the Oasis Method Development μ Elution™ Method Development plate, containing four mixed-mode Oasis SPE sorbents for rapid extraction method development. Linear and accurate bioanalytical quantitation from plasma was achieved using MCX SPE extraction and subsequent LC-MS/MS analysis.

Benefits

- Oasis μ Elution Method Development Plate, containing three rows each of MCX, WAX, WCX, and MAX mixed-mode Oasis SPE sorbents for fast mixed-mode SPE analyte method development
- High analyte recovery ($\geq 70\%$) and specificity (matrix effects $\leq 15\%$) using MM Oasis Sorbents, which includes both reversed-phase and ion-exchange functionality for orthogonal separation and retention
- Fast, three minute UPLC-MS analysis using the ACQUITY™ I-Class Plus UPLC™, ACQUITY UPLC CSH™ C₁₈

- Robust quantitative performance achieving linearity and accuracy of TKI oncology pharmaceuticals from plasma using MCX SPE extraction

Introduction

Bioanalytical LC-MS methods are essential for the accurate quantitation of next-generation therapies and generic equivalents in biological matrices. Developing these methods requires robust and efficient sample preparation strategies to ensure highly accurate, sensitive, and selective methods. Sample preparation plays a critical role in bioanalytical workflows, significantly impacting method complexity and development time, but drives the ultimate successful implementation of a method.

While it affords many benefits over other extraction techniques like protein precipitation or traditional reversed-phase solid phase extraction (SPE), mixed-mode (MM) SPE can be perceived as complex, often requiring lengthy protocol optimization to achieve high recovery and reproducibility required for analyte quantification from biological matrices. However, mixed-mode SPE provides enhanced selectivity over other techniques and is a good alternative if reversed-phase SPE is not providing adequate recovery or selectivity. In this application, the Oasis μ Elution Method Development Plate, containing three rows each of MCX, WAX, WCX, and MAX mixed-mode Oasis SPE sorbents, was used for preliminary MM SPE extraction screening of several block-buster oncology tyrosine kinase inhibitors (TKI) pharmaceuticals (Table 1) from plasma.¹ Excellent SPE recovery ($\geq 70\%$) and low matrix effects ($\leq 15\%$) was achieved using the MCX sorbent. Use of this method development plate with optimized protocols, enabled simple and rapid mixed-mode SPE screening in one experiment, which significantly reduced sample preparation method development time.

Final sample preparation and extraction of the TKI oncology pharmaceuticals from plasma was performed using the MM MCX 96-well μ Elution Plate and subsequent LC-MS/MS analysis. Linear and accurate bioanalytical quantification results were achieved for all analytes, with calibration curves ≥ 0.99 and accuracy $\geq 85\%$ across the calibration points.

Pharmaceutical drug trade name	Active pharmaceutical ingredient	Molecular weight (g/mol)	cLogP	pKa	pKb
BOSULIF®	Bosutinib	530.45	4.87	15.48	8.03
SPRYCEL®	Dasatinib	488.01	2.77	10.99	7.19
XALKORI®	Crizotinib	450.34	3.82	NA	10.12
IMBRUVICA®	Ibrutinib	440.50	2.76	19.70	6.58
CIBINQO®	Abrocitinib	323.41	0.93	11.47	6.45
ZOKINVY®	Lonafarnib	638.82	5.30	15.75	3.28
VANFLYTA®	Quizartinib	560.67	5.13	10.43	6.62
VONJO®	Pacritinib	472.58	4.78	14.10	8.86

Table 1. Small Molecule Pharmaceuticals and their physiochemical properties highlighted in this application.²

Experimental

UPLC Conditions

UPLC:	I-ClassPlus , FLwith Column Manager (CMA)
MPA:	0.1% FA in Water
MPB:	0.1% FA in Acetonitrile
Column:	ACQUITY UPLC CSH C ₁₈ Column, 130 Å, 1.7 µm, 2.1 mm x 30 mm (p/n: 186005295)
Column temperature:	45 °C
Sample temperature:	15 °C

Injection volume:	10 µL
Analysis time:	3.0 min
WNW:	90:10 Water:ACN+ 0.1% FA
SNW:	25:25:25:25 Water:IPA:ACN:MeOH

MS Conditions

MS:	Xevo TQ-XS
Capillary (kV):	0.75
Cone voltage:	45 V
Desolvation temperature:	500 °C
Desolvation flow:	1100 L/Hr
Cone gas flow:	150 L/Hr
Source temperature:	125 °C

UPLC Gradient Table

Time (min)	Flow rate (mL/min)	% MP A	% MP B
0.0	0.7	90	10
0.5	0.7	90	10
1.0	0.7	70	30
1.2	0.7	10	90
1.5	0.7	10	90
2.0	0.7	90	10
3.0	0.7	90	10

Data Management

All data was acquired and analyzed using Waters™ MassLynx™ Software v. 4.1 and quantification performed using TargetLynx™ Software.

Materials

The small molecule pharmaceuticals were purchased from Selleckchem (<https://www.selleckchem.com>) and from Cayman Chemicals (www.caymanchem.com <<http://www.caymanchem.com/>>) LC-MS grade formic acid, and phosphoric acid, and ammonium hydroxide were purchased from Sigma Aldrich (www.sigmaaldrich.com <<http://www.sigmaaldrich.com/>>). Methanol and Acetonitrile were purchased from Honeywell (lab.honeywell.com).

Sample Preparation and Extraction

Stock solutions of each individual pharmaceutical (1 mg/mL) were prepared in a 50:50 water: methanol solution. Aliquots of each 1 mg/mL pharmaceutical stock solution were combined to yield working stock solution mixtures of 50, 10, and 1 µg/mL, respectively. Initial SPE recovery and matrix effects evaluations were conducted using 0.5–1.0 µg/mL prepared in rat plasma using the Oasis µElution Sorbent Selection plate and 2 x 4 SPE protocol shown in Figure 1. Final SPE extraction from plasma was performed using the Oasis MCX 96-Well µElution Plate and analysis of the neutral fraction (Elute 1). Calibration curve samples were prepared between 0.91–1,000 ng/mL in plasma (300 µL). Loading of the acid pretreated plasma sample (1:1) was followed by a 200 µL wash of the sorbent with a 2% aqueous formic acid solution followed by a 2 x 25 µL elution of the TKI pharmaceuticals with 100% methanol. SPE extracted eluate was diluted with 50 µL of water prior to LC-MS/MS analysis.

Rapid mixed-mode SPE method development

Oasis Method Development 96-well μ Elution Plate, 2 mg Sorbent per well: P/N 186004475




Figure 1. Oasis mixed-mode method development protocol for rapid SPE method development using the Oasis Method Development plate, containing three rows each of the MM sorbents: MCX, WAX, WCX, and MAX.

Pharmaceutical analyte recovery was calculated according to the following equation:

$$\% \text{Recovery} = \left(\frac{\text{Area A}}{\text{Area B}} \right) \times 100\%$$

Where Area A = the peak area of an extracted sample in which the compounds were added pre-SPE extraction and Area B = the peak area of an extracted matrix sample in which the compounds were added post-SPE extraction.

Matrix effects were calculated according to the following equation:

$$\text{Matrix Effects} = \left(\left(\frac{\text{Peak area in presence of matrix}}{\text{Peak area in absence of matrix}} \right) - 1 \right) \times 100\%$$

The peak area in the presence of matrix refers to the peak area of an extracted blank matrix sample in which the compounds were added post-SPE extraction. The peak area in the absence of matrix refers to analytes in a neat solvent solution comprised of the final SPE eluate composition injected for analysis. In this case, methanol (neutral elution 1) and 5% NH₄OH and 2% formic acid in methanol (elution solutions 2) diluted 1:1 with water.

Results and Discussion

LC/MS Analysis

LC-MS/MS analysis was performed using a Waters Xevo TQ-XS Tandem Quadrupole MS using an electro spray ionization (ESI) source and Multi Reaction Monitoring (MRM). The MS MRM transitions for each pharmaceutical are listed in Table 2. Chromatographic separation of these analyte was performed using an ACQUITY I-Class PLUS UPLC System and ACQUITY UPLC CSH C₁₈ Column, 130 Å, 1.7 µm, 2.1 mm x 30 mm (p/n: [186005295 < https://www.waters.com/nextgen/global/shop/columns/186005295-acquity-uplc-csh-c18-column-130a-17--m-21-mm-x-30-mm-1-pk.html>](https://www.waters.com/nextgen/global/shop/columns/186005295-acquity-uplc-csh-c18-column-130a-17--m-21-mm-x-30-mm-1-pk.html)). The column temperature was 45 °C. Gradient separation using 0.1% formic acid in water, mobile phase A (MP A) and 0.1% formic acid in acetonitrile, mobile phase B (MP B) was employed. Initial LC conditions used a flow rate of 0.7 mL/min and 90% MP A, which was held for 0.5 minutes, followed by an increase to 30% MP B over 0.5 minutes, and then increased to 90% MP B over 0.2 minutes then held at 90% MP B for 0.3 minutes to flush the column and returned to starting gradient conditions at 2.0 minutes. Total analysis time was three minutes. Injection volumes of the extracted samples was 10 µL. An illustration of analyte chromatographic performance is illustrated in Figure 2.

Analyte	MRM Transition (<i>m/z</i>)	Collision energy (eV)
Bosutinib	530.20>112.80	40
	530.20>141.20	40
Dasatinib	488.17>232.75	30
	488.17>401.17	35
Crizotinib	450.34>177.00	30
	450.34>259.90	20
Ibrutinib	441.50>84.00	45
	441.50>137.90	40
	441.50>303.80	40
Abrocitinib	324.40>118.90	40
	324.40>133.90	30
	324.40>148.90	30
Lonafarnib	638.90>596.00	20
	638.90>621.90	40
Quizartinib	561.40>114.00	45
	561.40>307.80	40

Table 2. MS ESI mode, MRM transitions, and collision energy employed for each pharmaceutical.




Figure 2. LC chromatographic separation of the TKI oncology pharmaceuticals (250 ng/mL) using the ACQUITY UPLC CSH C₁₈ Column, 130 Å, 1.7 µm, 2.1 mm x 30 mm.

SPE Extraction

The Oasis mixed-mode sorbents were designed to help scientists achieve the highest level of sample cleanliness and analyte specificity. By combining the power of reversed-phase and ion-exchange retention mechanism, it is possible to design a targeted SPE method by choosing the appropriate Oasis sorbent.³⁻⁵ Using the Oasis 2 x 4 Method (Figure 1) in combination with the Oasis Sorbent Selection Plate, containing three rows each of MCX, WAX, WCX, and MAX mixed-mode Oasis SPE sorbents, facilitates fast MM SPE analyte screening in one experiment. Representative MM SPE screening results using this approach is illustrated in Figure 3 for the oncology pharmaceuticals, abrocitinib (A) and enzalutamide (B). In this case, high plasma recovery (100 µL) for both abrocitinib and enzalutamide was found using the MCX sorbent and 2 x 25 µL elution using elution solutions 1 and 2 shown in Figure 1. Abrocitinib eluted in the neutral fraction (elute 1) while enzalutamide recovery was greatest in the mixed-mode fraction (elute 2). The final MCX SPE protocol and plasma recovery and matrix effects for all TKI pharmaceuticals (Table 1) extracted from plasma is shown in Figure 4. With the exception of quizartinib, plasma recovery was greater than 70% from plasma, with no protocol modification required. Using a neat solution standard, quizartinib recovery was >75% (data not shown) pointing to plasma

protein binding as the source of low recovery. Future work would focus on modification of the sample pretreatment to effectively disrupt analyte: plasma protein binding to improve quizartinib recovery. In addition to high recovery, high analyte selectivity was achieved with matrix effects for the TKI oncology pharmaceuticals extracted from plasma between -11 and 10%.

Pharmaceutical drug trade name	Active pharmaceutical ingredient	Molecular weight (g/mol)	LogP	pKa	pKb
Xtandi®	Enzalutamide	464.44	3.75	13.05	-1.60
CIBINQO®	Abrocitinib	323.41	0.93	11.47	6.45




Figure 3. Representative plasma recovery resulting from the extraction of the pharmaceutical analytes abrocitinib (A) and enzalutamide (B) from plasma using the Oasis Method Development μ Elution Plate with its four mixed-mode sorbents (MCX, WAX, MAX, and WCX) in the 96-Well μ Elution format and the 2 by 4 SPE Method development protocols listed in Figure 1. Best recovery for abrocitinib was seen with the MCX sorbent and neutral fraction (elute 1), and the mixed-mode fraction (elute 2) for enzalutamide.




Figure 4. Representative recovery and matrix effects resulting from the extraction of the TKI oncology pharmaceutical analytes from plasma using the Oasis MCX (Elute 1 neutral fraction) and MCX SPE extraction protocol listed in Figure 1.

Bioanalytical Quantitation

Proof-of-concept bioanalytical quantification of the pharmaceutical analytes extracted from plasma was performed using the Oasis MCX 96-well μ Elution plate (p/n: [1860001830BA](https://www.waters.com/nextgen/global/shop/sample-preparation--filtration/186001830ba-oasis-mcx-96-well--elution-plate-2-mg-sorbent-per-well-30--m-1-p.html) < <https://www.waters.com/nextgen/global/shop/sample-preparation--filtration/186001830ba-oasis-mcx-96-well--elution-plate-2-mg-sorbent-per-well-30--m-1-p.html>>) using 300 μ L of plasma pretreated 1:1 with a 4% phosphoric acid solution to aid in protein binding disruption, as well as improve resonance time of the pharmaceutical analytes with the sorbent bed. Loading of the plasma sample was followed by a 200 μ L wash of the sorbent with a 2% aqueous formic acid solution followed by a 2 x 25 μ L elution of the TKI pharmaceuticals with 100% methanol. SPE extracted eluate was diluted with 50 μ L of water prior to LC-MS/MS analysis. Quantification performance from extracted plasma using the Oasis MCX MM sorbent in the μ Elution 96-well plate format is highlighted in Figure 5. Linear fit of calibration curves was >0.99. Lower limit of quantification (LLOQ) for all pharmaceuticals was 0.91 ng/mL, while upper limit of quantification (ULOQ) was 500 ng/mL for bosutinib, crizotinib, and pacritinib. ULOQ for ibrutinib and dasatinib was 1000 ng/mL and 125 ng/mL for

abrocitinib . Accuracy of all calibration points was $\pm 15\%$.




Figure 5. Representative quantification performance for the TKI oncology pharmaceuticals demonstrating linearity, accuracy, and precision across calibration points extracted from plasma using the MCX MM sorbent (Elute 1) in the 96-well μ Elution plate format.

Conclusion

This application highlights the successful SPE extraction and LC-MS/MS quantification of several small molecule TKI oncology pharmaceuticals from plasma using Oasis MCX SPE. Use of the Oasis Method Development Plate and 2x4 SPE protocol strategy greatly simplified MM SPE method development in one experiment, by easily screening four sorbents in one device. Using the Oasis MCX SPE for final bioanalytical extraction from plasma, provided excellent extraction performance, achieving high analyte recovery (70%) and low matrix effects ($\leq 15\%$), whilst also achieving linear (>0.99) and accurate (15%) quantitation.

References

1. Williams, RE and Leatherwood HM Top 200 Small Molecule Drugs by Retail Sales in 2023 <https://bpb-us-e2.wpmucdn.com/sites.arizona.edu/dist/9/130/files/2024/05/2023Top200SmallMoleculePosterV5.pdf> <<https://bpb-us-e2.wpmucdn.com/sites.arizona.edu/dist/9/130/files/2024/05/2023Top200SmallMoleculePosterV5.pdf>> (accessed 21 June 2024).
2. Drugbank Online <https://go.drugbank.com/drugs/DB00480> <<https://go.drugbank.com/drugs/DB00480>> (accessed 21 June 2024).
3. Chambers, E, Diehl, D, Mazzeo J, Simple and Fast SPE-UPLC-MS-MS Method for an Allery Tablet Mixture of Acids and Bases <https://www.waters.com/webassets/cms/library/docs/wa41942.pdf> <<https://www.waters.com/webassets/cms/library/docs/wa41942.pdf>>
4. Danaceau, JP, Trudeau ME, A Simple, Broadly Applicable Automated Bioanalytical Sample Preparation Strategy for LC-MS Quantification of Apixaban: Evaluation of Common Bioanalytical Extraction Techniques. Waters Application Note. [720007946](#). July 2023.
5. Rahim F, VanTran, Trudeau ME, Simple, Fast and Selective, Bioanalytical Sample Extraction for the Therapeutic Drug, Lenalidomide From Plasma Using Oasis MCX SPE. Waters Application Note. [720008140](#) . December 2023.

Featured Products

ACQUITY UPLC I-Class PLUS System <<https://www.waters.com/134613317>>

Xevo TQ-XS Triple Quadrupole Mass Spectrometry <<https://www.waters.com/134889751>>

MassLynx MS Software <<https://www.waters.com/513662>>

TargetLynx <<https://www.waters.com/513791>>

720008447, July 2024



© 2024 Waters Corporation. All Rights Reserved.

[Terms of Use](#) [Privacy Policy](#) [Trademarks](#) [Careers](#) [Legal and Privacy Notices](#) [Cookies](#)
[Cookie Preferences](#)